The chronic respiratory disorders pharmaceutical specialist Pharmaxis completed the development of its experimental drug, the Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor (PXS4728A), which is designed to treat several forms of chronic inflammation ... Read more